Retatrutide (LY-3437943) — Triple-Agonist Research Peptide
Push metabolic-disease investigation forward with Retatrutide, the once-weekly synthetic peptide that co-activates GLP-1, GIP and glucagon receptors. In Phase 2 studies, participants lost up to 24 % of body weight after 48 weeks, positioning Retatrutide at the forefront of next-generation obesity and T2D therapeutics.
-
Purity: > 99 % (HPLC)
-
Molecular Weight: ≈ 4.8 kDa
-
Form & Sizes: Lyophilized powder in 10 mg and 30 mg research-grade vials
-
Solubility: Sterile water or 0.6 % saline
-
Storage: −20 °C long-term; aliquoted reconstitutions ≤ −80 °C
For laboratory research use only. Not for human administration.